Stroke

Preclinical stroke researchers typically rely on infarct volume (MRI or TTC staining), motor deficit scoring (Bederson scale, rotarod, cylinder test), and histological measures of neuronal death as primary outcome measures. These readouts either require terminal procedures (TTC, histology) or capture only a subset of functional deficits. The retinal and visual consequences of cerebral ischemia – even when substantial and clinically meaningful – remain systematically unmeasured in most preclinical stroke studies, representing a gap between the animal model and the ~60-73% of human stroke survivors who experience significant visual impairment (Rowe et al, 2019, PLoS ONE; Li et al, 2022, Eye).

Because the ophthalmic artery originates proximal to the MCA, intraluminal filament MCAO in rodents simultaneously interrupts retinal and cerebral perfusion. Retinal ganglion cells (RGCs) are exquisitely sensitive to ischemia and begin undergoing apoptosis within hours of vascular occlusion. RGC loss reduces the magnitude of the optomotor reflex before any gross retinal structural change is visible, meaning functional visual testing can detect injury earlier than most histological endpoints. Critically, this sensitivity comes without the need for anesthesia, surgical access, or contrast agents – making it repeatable at any time point throughout the study. For a focused discussion of the RGC and optic nerve dimension of this process, see Retinal Ganglion Cell Pathology and Neurovascular Injury.

The concept of neurovascular coupling – the tight coordination of local neural activity with microvessel blood flow – is central to understanding both normal visual function and its disruption by stroke. RGCs have high ATP demands and are among the first neurons to fail during ischemia; inner retinal layers begin showing electrophysiological dysfunction within 5-10 minutes of complete vascular occlusion. Downstream, the optic nerve axons – unmyelinated in the retinal portion but myelinated after the lamina cribrosa – are vulnerable to ischemic demyelination, a mechanism shared with multiple sclerosis and relevant to the post-ischemic axon degeneration discussed in the axon degeneration cluster.

Post-stroke neuroinflammation further uncouples the neurovascular unit: activated microglia and recruited peripheral immune cells release TNF-α, IL-1β, and reactive oxygen species that amplify ischemic cell death in the peri-infarct zone. For a detailed treatment of the neuroinflammation dimension, see the neurovascular injury cluster and the Vascular and Metabolic Disease overview. Disentangling retinal from cortical contributions to the visual deficit requires assays that can be independently assigned to each circuit level.

The translation failure rate for neuroprotective drugs in stroke is high: more than 1000 compounds have shown efficacy in rodent models but failed in human trials. A key contributor to this gap is the narrow range of functional endpoints used in preclinical screens. Standard stroke models assess infarct volume, motor scores, and often a single cognitive test; visual function is rarely included despite the high clinical burden of post-stroke visual impairment. Incorporating a functional visual endpoint offers several advantages for drug screens: it is quantitative and continuous (unlike categorical clinical scoring), it can be repeated longitudinally without additional animal groups, it is sensitive to treatment at both the retinal and subcortical visual-circuit levels, and it avoids the anesthesia confounds of electrophysiological endpoints.

For cell-based and gene-therapy approaches in particular, the retinal visual system provides an accessible window: subretinal or intravitreal delivery can be validated by functional OptoDrum readout, while a concurrent systemic or CNS-directed treatment can be evaluated for its effect on the same retinal endpoint. This dual-window approach – cerebroprotective and retino-protective effects measured with a single behavioral assay – is uniquely enabled by the neurovascular anatomy of focal ischemia. See also the therapeutic recovery angle in the retinal ischemia-reperfusion injury cluster.

Stroke researchers who wish to add a visual endpoint to their study face a choice between methods that differ substantially in invasiveness, throughput, anesthesia requirements, the circuit level they sample, and their suitability for repeated longitudinal measurements. A mismatch between method and question – for example, using a purely retinal assay to measure visual cortex recovery – produces uninterpretable data. Understanding which assay is appropriate for which question is therefore a prerequisite for experimental design. The detailed comparison is presented in the Modality Comparison Table in Section 6 below.